Status and physiological significance of circulating adiponectin in the very old and centenarians: an observational study

  1. Takashi Sasaki  Is a corresponding author
  2. Yoshinori Nishimoto
  3. Takumi Hirata
  4. Yukiko Abe
  5. Nobuyoshi Hirose
  6. Michiyo Takayama
  7. Toru Takebayashi
  8. Hideyuki Okano
  9. Yasumichi Arai
  1. Keio University, Japan
  2. Nara Medical University, Japan
  3. Houtokukai Utsunomiya Hospital, Japan

Abstract

Background: High levels of circulating adiponectin are associated with increased insulin sensitivity, low prevalence of diabetes, and low body mass index (BMI); however, high levels of circulating adiponectin are also associated with increased mortality in the 60-70 age group. In this study, we aimed to clarify factors associated with circulating high-molecular-weight (cHMW) adiponectin levels and their association with mortality in the very old (85-89 years old) and centenarians.

Methods: The study included 812 (women: 84.4%) for centenarians and 1,498 (women: 51.7%) for the very old. The genomic DNA sequence data were obtained by whole genome sequencing or DNA microarray-imputation methods. LASSO and multivariate regression analyses were used to evaluate cHMW adiponectin characteristics and associated factors. All-cause mortality was analyzed in three quantile groups of cHMW adiponectin levels using Cox regression.

Results: The cHMW adiponectin levels were increased significantly beyond 100 years of age, were negatively associated with diabetes prevalence, and were associated with SNVs in CDH13 (p = 2.21 × 10-22) and ADIPOQ (p = 5.72 × 10-7). Multivariate regression analysis revealed that genetic variants, BMI, and high-density lipoprotein cholesterol (HDLC) were the main factors associated with cHMW adiponectin levels in the very old, whereas the BMI showed no association in centenarians. The hazard ratios for all-cause mortality in the intermediate and high cHMW adiponectin groups in very old men were significantly higher rather than those for all-cause mortality in the low level cHMW adiponectin group, even after adjustment with BMI. In contrast, the hazard ratios for all-cause mortality were significantly higher for high cHMW adiponectin groups in very old women, but were not significant after adjustment with BMI.

Conclusions: cHMW adiponectin levels increased with age until centenarians, and the contribution of known major factors associated with cHMW adiponectin levels, including BMI and HDLC, varies with age, suggesting that its physiological significance also varies with age in the oldest old.

Funding: This study was supported by grants from the Ministry of Health, Welfare, and Labour for the Scientific Research Projects for Longevity; a Grant-in-Aid for Scientific Research (No 21590775, 24590898, 15KT0009, 18H03055, 20K20409, 20K07792, 23H03337) from the Japan Society for the Promotion of Science; Keio University Global Research Institute (KGRI), Kanagawa Institute of Industrial Science and Technology (KISTEC), Japan Science and Technology Agency (JST) Research Complex Program 'Tonomachi Research Complex' Wellbeing Research Campus: Creating new values through technological and social innovation (JP15667051), the Program for an Integrated Database of Clinical and Genomic Information from the Japan Agency for Medical Research and Development (No. 16kk0205009h001, 17jm0210051h0001, 19dk0207045h0001); the medical-welfare-food-agriculture collaborative consortium project from the Japan Ministry of Agriculture, Forestry, and Fisheries; and the Biobank Japan Program from the Ministry of Education, Culture, Sports, and Technology.

Data availability

The cHMW adiponectin levels and covariates data were deposited with this manuscript as source data files. The data with age for the very old and centenarians have ethical and legal restrictions to public deposition due to avoid personal identification, and will be available upon request with an appropriate research arrangement with approval of the Research Ethics Committee of Keio University School of Medicine for Clinical Research. To request, please contact Takashi Sasaki (corresponding author) via e-mail: sasasa@z5.keio.jp.

Article and author information

Author details

  1. Takashi Sasaki

    Center for Supercentenarian Medical Research, Keio University, Tokyo, Japan
    For correspondence
    sasasa@z5.keio.jp
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-6275-046X
  2. Yoshinori Nishimoto

    Center for Supercentenarian Medical Research, Keio University, Tokyo, Japan
    Competing interests
    No competing interests declared.
  3. Takumi Hirata

    Institute for Clinical and Translational Science, Nara Medical University, Nara, Japan
    Competing interests
    No competing interests declared.
  4. Yukiko Abe

    Center for Supercentenarian Medical Research, Keio University, Tokyo, Japan
    Competing interests
    No competing interests declared.
  5. Nobuyoshi Hirose

    Houtokukai Utsunomiya Hospital, Tochigi, Japan
    Competing interests
    No competing interests declared.
  6. Michiyo Takayama

    Center for Supercentenarian Medical Research, Keio University, Tokyo, Japan
    Competing interests
    No competing interests declared.
  7. Toru Takebayashi

    Center for Supercentenarian Medical Research, Keio University, Tokyo, Japan
    Competing interests
    No competing interests declared.
  8. Hideyuki Okano

    Center for Supercentenarian Medical Research, Keio University, Tokyo, Japan
    Competing interests
    Hideyuki Okano, received consulting fees from SanBio Co.Ltd and K Pharma Inc., and participates on the Advisory Board for both SanBio Co.Ltd and K Pharma Inc. The author is President of the Japanese Society for Regenerative Medicine and the Japanese Society for Neurochemistry. The author has no other competing interests to declare..
  9. Yasumichi Arai

    Center for Supercentenarian Medical Research, Keio University, Tokyo, Japan
    Competing interests
    Yasumichi Arai, has received a grant from the Cyclic Innovation for Clinical Empowerment (AMED EKID), and from DAIICHI SANKYO Co, Ltd. The author has no other competing interests to declare..

Funding

A GRANT-IN-AID FOR SCIENTIFIC RESEARCH (21590775)

  • Nobuyoshi Hirose
  • Michiyo Takayama
  • Yasumichi Arai

Japan Agency for Medical Research and Development (17jm0210051h0001)

  • Takashi Sasaki
  • Yasumichi Arai

Japan Agency for Medical Research and Development (19dk0207045h0001)

  • Takashi Sasaki
  • Yasumichi Arai

Keio University Global Research Institute

  • Hideyuki Okano
  • Yasumichi Arai

Kanagawa Institute of Industrial Science and Technology

  • Yasumichi Arai

A GRANT-IN-AID FOR SCIENTIFIC RESEARCH (24590898)

  • Nobuyoshi Hirose
  • Yasumichi Arai

A GRANT-IN-AID FOR SCIENTIFIC RESEARCH (15KT0009)

  • Yasumichi Arai

A GRANT-IN-AID FOR SCIENTIFIC RESEARCH (18H03055)

  • Yasumichi Arai

A GRANT-IN-AID FOR SCIENTIFIC RESEARCH (20K20409)

  • Takashi Sasaki
  • Yasumichi Arai

A GRANT-IN-AID FOR SCIENTIFIC RESEARCH (20K07792)

  • Takashi Sasaki
  • Yasumichi Arai

A GRANT-IN-AID FOR SCIENTIFIC RESEARCH (23H03337)

  • Takashi Sasaki
  • Yasumichi Arai

Japan Science and Technology Agency (JP15667051)

  • Toru Takebayashi
  • Yasumichi Arai

Japan Agency for Medical Research and Development (16kk0205009h001)

  • Yasumichi Arai

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Edward D Janus, University of Melbourne, Australia

Ethics

Human subjects: Written informed consent was obtained either from the participant or from a proxy if the participant lacked the capacity to provide consent. The ethics committee approved all cohort studies of the Keio University School of Medicine (ID: 20021020, 20022020, 20070047, and 20160297). The TOOTH and KAWP studies are registered in the University Hospital Medical Information Network Clinical Trial Registry (ID: UMIN000001842 and UMIN000026053).

Version history

  1. Preprint posted: June 30, 2022 (view preprint)
  2. Received: January 19, 2023
  3. Accepted: September 28, 2023
  4. Accepted Manuscript published: September 28, 2023 (version 1)
  5. Version of Record published: October 10, 2023 (version 2)

Copyright

© 2023, Sasaki et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 417
    views
  • 88
    downloads
  • 1
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Takashi Sasaki
  2. Yoshinori Nishimoto
  3. Takumi Hirata
  4. Yukiko Abe
  5. Nobuyoshi Hirose
  6. Michiyo Takayama
  7. Toru Takebayashi
  8. Hideyuki Okano
  9. Yasumichi Arai
(2023)
Status and physiological significance of circulating adiponectin in the very old and centenarians: an observational study
eLife 12:e86309.
https://doi.org/10.7554/eLife.86309

Share this article

https://doi.org/10.7554/eLife.86309

Further reading

    1. Biochemistry and Chemical Biology
    2. Computational and Systems Biology
    Richard Sejour, Janet Leatherwood ... Bruce Futcher
    Research Article

    Previously, Tuller et al. found that the first 30–50 codons of the genes of yeast and other eukaryotes are slightly enriched for rare codons. They argued that this slowed translation, and was adaptive because it queued ribosomes to prevent collisions. Today, the translational speeds of different codons are known, and indeed rare codons are translated slowly. We re-examined this 5’ slow translation ‘ramp.’ We confirm that 5’ regions are slightly enriched for rare codons; in addition, they are depleted for downstream Start codons (which are fast), with both effects contributing to slow 5’ translation. However, we also find that the 5’ (and 3’) ends of yeast genes are poorly conserved in evolution, suggesting that they are unstable and turnover relatively rapidly. When a new 5’ end forms de novo, it is likely to include codons that would otherwise be rare. Because evolution has had a relatively short time to select against these codons, 5’ ends are typically slightly enriched for rare, slow codons. Opposite to the expectation of Tuller et al., we show by direct experiment that genes with slowly translated codons at the 5’ end are expressed relatively poorly, and that substituting faster synonymous codons improves expression. Direct experiment shows that slow codons do not prevent downstream ribosome collisions. Further informatic studies suggest that for natural genes, slow 5’ ends are correlated with poor gene expression, opposite to the expectation of Tuller et al. Thus, we conclude that slow 5’ translation is a ‘spandrel’--a non-adaptive consequence of something else, in this case, the turnover of 5’ ends in evolution, and it does not improve translation.

    1. Biochemistry and Chemical Biology
    Boglarka Zambo, Evelina Edelweiss ... Gergo Gogl
    Research Article

    Truncation of the protein-protein interaction SH3 domain of the membrane remodeling Bridging Integrator 1 (BIN1, Amphiphysin 2) protein leads to centronuclear myopathy. Here, we assessed the impact of a set of naturally observed, previously uncharacterized BIN1 SH3 domain variants using conventional in vitro and cell-based assays monitoring the BIN1 interaction with dynamin 2 (DNM2) and identified potentially harmful ones that can be also tentatively connected to neuromuscular disorders. However, SH3 domains are typically promiscuous and it is expected that other, so far unknown partners of BIN1 exist besides DNM2, that also participate in the development of centronuclear myopathy. In order to shed light on these other relevant interaction partners and to get a holistic picture of the pathomechanism behind BIN1 SH3 domain variants, we used affinity interactomics. We identified hundreds of new BIN1 interaction partners proteome-wide, among which many appear to participate in cell division, suggesting a critical role of BIN1 in the regulation of mitosis. Finally, we show that the identified BIN1 mutations indeed cause proteome-wide affinity perturbation, signifying the importance of employing unbiased affinity interactomic approaches.